News overview
Story
25 November 2021
Oncode shows it can be done in a different way: an interview with Hans Clevers
How can we as a society benefit even more from the knowledge that is being developed at our Dutch universities? How do you transfer this knowledge into innovations that boost our economy and offer solutions to our major societal challenges? These are some of the questions at the core of Oncode Institute. Oncode Investigator Hans Clevers, co-founder of Oncode Institute and professor Molecular Genetics at Utrecht University and UMC Utrecht answers them in this interview conducted by Teachleap.nl in collaboration with Innovation Origins.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Story
25 November 2021
Oncode Investigator Sylvie Noordermeer: ‘Setting up your own research group is both exciting ánd terrifying’
Creating your own research group is exciting, but what are some of the typical challenges that can emerge? Oncode Investigator Sylvie Noordermeer (LUMC) discusses her experiences as founder of the Noordermeer research group, whilst also reflecting on the contribution that Oncode’s Mentoring Programme can make in solving dilemmas.
News
17 November 2021
Oncode-PACT proposal submitted to Growth Fund
Oncode Institute is proud to announce that the Ministry of Economic Affairs and Climate Policy formally decided to submit the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) proposal to the Growth Fund (Groeifonds) Commission on November 1st, 2021.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
16 November 2021
Clinical trial with new lung cancer vaccine started
Last week a new clinical trial with a vaccine against non-small cell lung cancer started at Erasmus MC. The vaccine teaches the immune system of lung cancer patients to recognize and clear tumor cells. Developed in the lab of Oncode Investigator Sjoerd van der Burg at Leiden University Medical Center, the technology may offer relief to a large proportion of the nearly 10,000 patients who receive this diagnosis each year.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
10 November 2021
A wrap-up of the Clinical Workshop Melanoma: looking into present approaches and what the future looks like
Due to restrictions linked to the pandemic, the Clinical Workshop Melanoma had to be postponed from last year to October this year. The restrictions relaxed and finally being able to come together, the long-expected event could take place. We now look back at a successful workshop that took place on the 5th of October at the Oncode office in Utrecht. The goal of the event was to bring together clinicians and clinical and basic researchers to discuss the tumor type melanoma, and to discuss current trends and unmet needs both within the clinic and in (clinical) research. The workshop aimed to also explore how basic research can address these unmet clinical needs and to stimulate new collaborations through translational and clinical projects.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
9 November 2021
Facility success stories: NKI Robotics and Screening Center
Investing in new technologies and facilities - which are available to all Oncode researchers - is one of the ways in which Oncode contributes to breakthroughs in cancer research. The Oncode drug screening centres of expertise at the LUMC and the NKI are examples of such facilities. They provide Oncode researchers with advice and support to perform complex compound screens with the Drug Repurposing library. Researcher Przemek Krawczyk discusses his experiences so far.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
In the spotlight
22 July 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
28 October 2021
In memoriam: Boelien Geerts
Sadly, we received the news that Boelien Geerts, one of the first patient representatives of Oncode’s Patient Engagement Programme, passed away on October 14 from the effects of lung cancer. Her absence will certainly be felt. We can openly say that Boelien was very active and committed to Oncode Institute’s efforts and mission. She contributed to our Patient Engagement Programme and inspired our researchers through her novel ideas, perspectives, and discussions based on her personal experiences and knowledge, and driven by a lot of enthusiasm.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
21 October 2021
In memoriam: David Morse Livingston, MD
Oncode Institute and its research community were saddened by the news of the unexpected death of David M. Livingston, MD. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center; Chief of the Charles A. Dana Division of Human Cancer Genetics, and the Emil Frei Professor of Genetics and Medicine at Harvard Medical School. He was also the chair of Oncode’s International Advisory Board.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
21 October 2021
Oncode Institute supports new preclinical collaboration between HepaRegeniX and the NKI
HepaRegeniX GmbH, a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced a collaboration with the NKI to investigate HepaRegeniX’ new drug candidate HRX-0233 in preclinical in vivo models with Kirsten rat sarcoma virus (KRAS) mutant tumors. Oncode’s Valorization Team supported the contract negotiations.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
19 October 2021
New research uncovers growth dynamics of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease and patients diagnosed with PDAC have a very poor prognosis. It has been speculated that a rare population of cancer stem cells (CSCs) are responsible for tumor growth, therapy resistance, and rapid metastatic progression in PDAC. The purported CSC populations were discovered by in vitro clonogenic assays and transplantation assays in mice. However, their relevance in established PDAC tissue has not been determined. Importantly these assays were mostly dependent on the expression of a specific marker, therefore the functionality of cell populations not expressing these markers remained untested. A new study by Oncode Investigator Louis Vermeulen and co-investigators Sophie Lodestijn and Maarten Bijlsma (all Amsterdam UMC), published today in Cell Reports, changes that. Their results can have important implications for the treatment of PDAC.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Scroll for more